Shakiness, cold sweat, sudden intense hunger, pounding heart, confusion or slurred speech — a blood-sugar crash, which this compound can trigger fast.
Take fast sugar immediately — juice, regular (non-diet) soda, or glucose tablets. Do not try to wait it out. Recheck after 15 minutes and repeat if still low.
If the person becomes confused, cannot swallow safely, has a seizure, or passes out, call 911 — this can be fatal, and crashes from IGF-1 can be severe and prolonged.
Allergic reaction: hives, swelling of the lips, tongue or throat, wheezing or dizziness can escalate to anaphylaxis within minutes — call 911 immediately. Site infection: spreading redness, heat, swelling, pus or fever is not wait-and-see; an abscess or cellulitis can need drainage or IV antibiotics. Unverified product: grey-market vials are frequently mislabelled or contaminated, so a reaction may be to endotoxin or the wrong contents, not the named compound.
Human amylin aggregates into amyloid fibrils, which makes it undruggable. Pramlintide substitutes three prolines — borrowed from rat amylin, which does not aggregate — producing a soluble analog with retained activity. It slows gastric emptying, suppresses inappropriate postprandial glucagon, and promotes satiety via the area postrema. It is the approved proof-of-concept for the mechanism cagrilintide is now pursuing.
Approved in 2005 on trials in type 1 and type 2 diabetes as mealtime adjunct therapy to insulin. Commercially marginal, but the pharmacology is established.
FDA-approved as adjunct mealtime therapy with insulin in type 1 and type 2 diabetes. Prescription-only.
Boxed warning for severe insulin-induced hypoglycaemia, typically within three hours of dosing. Requires concurrent insulin dose reduction and close glucose monitoring — this is genuinely a drug that kills people who use it casually. Nausea is common.
Type 1 diabetes: 15 mcg before meals, titrated to 30–60 mcg. Type 2: 60 mcg, up to 120 mcg. Given only with a mandatory reduction in mealtime insulin. FDA-label.
Reported from clinical trials or FDA labelling as a matter of record. It is not a recommendation, and for unapproved compounds no dose has been shown safe or effective in humans.
Above is what was administered in trials or on FDA labels, reported as fact. We do not convert it into a personal protocol, calculate a dose for your body weight, or tell you what to inject or how to reconstitute it — that decision belongs with a licensed physician. See our editorial policy.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.